Overactive Bladder - Pipeline Review, H2 2016

Date: October 12, 2016
Pages: 124
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OB23D9F437DEN
Leaflet:

Download PDF Leaflet

Overactive Bladder - Pipeline Review, H2 2016
Overactive Bladder - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H2 2016, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 4, 4, 2, 10 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Overactive Bladder.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Overactive Bladder Overview
Therapeutics Development
Pipeline Products for Overactive Bladder - Overview
Pipeline Products for Overactive Bladder - Comparative Analysis
Overactive Bladder - Therapeutics under Development by Companies
Overactive Bladder - Therapeutics under Investigation by Universities/Institutes
Overactive Bladder - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Overactive Bladder - Products under Development by Companies
Overactive Bladder - Products under Investigation by Universities/Institutes
Overactive Bladder - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Allergan Plc
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
Dompe Farmaceutici S.p.A.
Dong-A Socio Holdings Co. Ltd.
FemmePharma Global Healthcare, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hydra Biosciences, Inc.
Ion Channel Innovations, LLC
Ipsen S.A.
Jeil Pharmaceutical Co., Ltd.
Juniper Pharmaceuticals, Inc.
Lipella Pharmaceuticals, Inc.
Merck & Co., Inc.
Mezzion Pharma Co. Ltd.
Ono Pharmaceutical Co., Ltd.
Recordati S.p.A.
Sanofi
Seoul Pharma Co., Ltd.
Taris Biomedical LLC
TheraVida, Inc.
Toray Industries, Inc.
UroGen Pharmaceuticals, Ltd.
XuanZhu Pharma Co., Ltd.
Overactive Bladder - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(mirabegron + solifenacin succinate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-8010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFL-23448 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HC-067047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIP-1503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirabegron ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-8577 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pVAX-hSlo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-0438 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-244181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solabegron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solifenacin succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPO-1406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tacrolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAR-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THVD-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vibegron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Overactive Bladder - Dormant Projects
Overactive Bladder - Discontinued Products
Overactive Bladder - Product Development Milestones
Featured News & Press Releases
Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver
May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego
Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women
Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product
Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting
Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting
Dec 08, 2014: Lipella’s Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial
Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder
Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder
Sep 11, 2013: Allergan's BOTOX Receives Authorisation for the Treatment of Overactive Bladder in the UK
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441
May 17, 2013: Astellas's Betmiga Obtains NICE Recommendation For Restricted Use In Treatment Of Overactive Bladder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 124

LIST OF TABLES

Number of Products under Development for Overactive Bladder, H2 2016
Number of Products under Development for Overactive Bladder - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H2 2016
Overactive Bladder - Pipeline by Allergan Plc, H2 2016
Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp., H2 2016
Overactive Bladder - Pipeline by Astellas Pharma Inc., H2 2016
Overactive Bladder - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
Overactive Bladder - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
Overactive Bladder - Pipeline by FemmePharma Global Healthcare, Inc., H2 2016
Overactive Bladder - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Overactive Bladder - Pipeline by Hydra Biosciences, Inc., H2 2016
Overactive Bladder - Pipeline by Ion Channel Innovations, LLC, H2 2016
Overactive Bladder - Pipeline by Ipsen S.A., H2 2016
Overactive Bladder - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
Overactive Bladder - Pipeline by Juniper Pharmaceuticals, Inc., H2 2016
Overactive Bladder - Pipeline by Lipella Pharmaceuticals, Inc., H2 2016
Overactive Bladder - Pipeline by Merck & Co., Inc., H2 2016
Overactive Bladder - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
Overactive Bladder - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Overactive Bladder - Pipeline by Recordati S.p.A., H2 2016
Overactive Bladder - Pipeline by Sanofi, H2 2016
Overactive Bladder - Pipeline by Seoul Pharma Co., Ltd., H2 2016
Overactive Bladder - Pipeline by Taris Biomedical LLC, H2 2016
Overactive Bladder - Pipeline by TheraVida, Inc., H2 2016
Overactive Bladder - Pipeline by Toray Industries, Inc., H2 2016
Overactive Bladder - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016
Overactive Bladder - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Overactive Bladder - Dormant Projects, H2 2016
Overactive Bladder - Dormant Projects (Contd..1), H2 2016
Overactive Bladder - Dormant Projects (Contd..2), H2 2016
Overactive Bladder - Dormant Projects (Contd..3), H2 2016
Overactive Bladder - Dormant Projects (Contd..4), H2 2016
Overactive Bladder - Dormant Projects (Contd..5), H2 2016
Overactive Bladder - Discontinued Products, H2 2016
Overactive Bladder - Discontinued Products (Contd..1), H2 2016 112

LIST OF FIGURES

Number of Products under Development for Overactive Bladder, H2 2016
Number of Products under Development for Overactive Bladder - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Overactive Bladder Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 226 pages

Ask Your Question

Overactive Bladder - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: